AstraZeneca Pharma India Limited has secured regulatory approval from the Central Drugs Standard Control Organization (CDSCO) for its oncology drug Enhertu (Trastuzumab Deruxtecan) for an additional indication in India. The approval, received on July 27, 2026, permits the import, sale, and distribution of the drug for the neoadjuvant treatment of adult patients with HER2-positive Stage II or III breast cancer. This development expands the therapeutic options available for early-stage breast cancer patients in the country.

The regulatory clearance specifically covers the use of Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion. Under the approved protocol, the drug is indicated for use followed by a taxane, trastuzumab, and pertuzumab (THP). The approval applies to adult patients diagnosed with HER2-positive breast cancer, defined as IHC 3+ or ISH+, at Stage II or Stage III. The company notified the stock exchanges of this development on July 28, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Approval Details

The following table outlines the key parameters of the regulatory clearance granted by the Directorate General of Health Services, Government of India:

Clinical Significance

The neoadjuvant setting refers to treatment administered prior to primary surgical intervention. Therapies in this phase aim to reduce tumor size and improve surgical outcomes. By securing approval for Enhertu in this specific context, AstraZeneca broadens the landscape of targeted oncology therapies available in India. HER2-positive breast cancer is characterized by elevated expression of the human epidermal growth factor receptor 2 protein, making targeted therapies a critical area of development.

Market Implications

The receipt of permission from the CDSCO paves the way for the marketing of Enhertu in India for this additional indication. The commercial launch remains subject to the receipt of related statutory approvals, if any. This expansion aligns with global treatment standards, offering Indian patients access to advanced targeted therapies that address specific biological markers of the disease. The approval strengthens AstraZeneca’s portfolio in the oncology segment, particularly in early-stage breast cancer management.

AstraZeneca (NASDAQ: AZN) reported second-quarter 2026 results that delivered an earnings beat but fell short on revenue expectations, even as the company navigated mixed outcomes from key late-stage clinical trials. The pharmaceutical giant posted adjusted earnings per share (EPS) of $2.63, surpassing the analyst consensus estimate of $2.48 by approximately 6%. However, quarterly revenue came in at $15.384 billion, missing the expected $15.459 billion. Despite the top-line miss, CEO Pascal Soriot reaffirmed the company’s $80 billion total revenue ambition for 2026, citing confidence in its pipeline despite recent setbacks.

The financial performance was driven by strong growth in the oncology portfolio, which accounted for 48% of product revenue and rose 16% year-over-year to $7.33 billion. Key contributors included Enhertu, which saw revenue jump 33% to $888 million, and Imfinzi, which grew 27% to $1.85 billion. Conversely, the cardiovascular, renal, and metabolism segment declined 18% at constant currency, with Farxiga revenue falling 16% to $1.804 billion. Respiratory and Immunology revenue increased 13% to $2.43 billion, while rare disease revenue climbed 9% to $2.49 billion, led by Ultomiris sales of $1.31 billion.

Financial Performance Metrics

Pipeline Developments and Trial Results

AstraZeneca shared high-level results from two significant Phase 3 trials. The ALXN1210-TMA-313 study of Ultomiris (ravulizumab) in patients with thrombotic microangiopathy (TMA) after hematopoietic stem cell transplant (HSCT) did not achieve statistical significance for its primary endpoint of event-free survival through 26 weeks compared to placebo. However, the company noted a trend toward treatment benefit in adults and adolescents and is advancing regulatory filings for pediatric patients based on overall survival data showing 87.2% survival at 26 weeks.

In oncology, the CLARITY-Gastric01 trial of sonesitatug vedotin (Sone-Ve) for advanced gastric cancers demonstrated a statistically significant improvement in overall survival versus investigator’s choice of therapy. While Sone-Ve showed a trend toward improved progression-free survival, it did not reach statistical significance for that secondary endpoint. The drug was well-tolerated with no new safety signals identified.

What the Numbers Show

The divergence between the substantial EPS growth of 141.28% and the modest revenue increase of 6.41% highlights AstraZeneca’s focus on margin expansion and operational efficiency. While the revenue miss was narrow, the strength in high-growth oncology products like Enhertu and Imfinzi offset declines in mature assets such as Farxiga. The mixed clinical data presents a nuanced picture: while the Ultomiris setback in adults is a disappointment, the push for pediatric approval maintains a pathway for value realization. Similarly, Sone-Ve’s overall survival benefit supports its potential as a later-line gastric cancer treatment, despite missing the progression-free survival endpoint. These developments underscore the volatility inherent in late-stage development, yet management’s reiterated guidance suggests these individual setbacks do not derail the broader financial trajectory.